PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development

Prostate cancer is globally the second most commonly diagnosed cancer type in men. Recent studies suggest that mutations in DNA repair genes are associated with aggressive forms of prostate cancer and castration resistance. Prostate cancer with DNA repair defects may be vulnerable to therapeutic tar...

Descripción completa

Detalles Bibliográficos
Autores principales: Virtanen, Verneri, Paunu, Kreetta, Ahlskog, Johanna K., Varnai, Reka, Sipeky, Csilla, Sundvall, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723995/
https://www.ncbi.nlm.nih.gov/pubmed/31357527
http://dx.doi.org/10.3390/genes10080565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723995/
https://www.ncbi.nlm.nih.gov/pubmed/31357527
http://dx.doi.org/10.3390/genes10080565

Ejemplares similares